PCSK9 inhibitor pill -- probably a game changer.
Merck's oral PCSK9 pill Lipfendra approved by FDA, cut LDL 56-60% in Phase 3
Reports FDA approval of Merck's Lipfendra, a once-daily pill delivering PCSK9-inhibitor-type LDL lowering. Phase 3 trials showed LDL reductions of 56% to 60%.



